View Clinical Trial (Medical Research Study)
Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression
| City: |
|
New Haven |
| State: |
|
Connecticut |
| Zip Code: |
|
06519 |
| Conditions: |
|
Bipolar Depression |
| Purpose: |
|
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient,
placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar
disorder, currently depressed, who have failed to respond to conventional treatments.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- DSM-IV diagnosis of bipolar disorder
- Presence of a current major depressive episode on the SCID
- Score of 17 or greater on the HDRS
- Failure to respond to two previous medication trials
- Capable of giving voluntary written consent
Exclusion Criteria:
- Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis
- Significant current substance dependence/abuse within 3 months preceding the trial
- Significant history of intravenous drug abuse
- Active suicidal ideation
- Pregnant/lactating mothers
- Significant medical history
- Patients on anticoagulation treatment
- Patients who test positive for HIV or Hep B or C
|
| NCT ID: |
|
NCT00566111 |
| Primary Contact: |
|
Principal Investigator
Zubin Bhagwagar, MD PhD
Yale University
Kathleen Maloney, BA
Phone: 203-974-7496
Email: kathleen.maloney@yale.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
New Haven, Connecticut 06519
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|